BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Ilumya (tildrakizumab) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Ilumya (tildrakizumab)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05390515-99@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20280901
DTEND;VALUE=DATE:20280902
SUMMARY:Ilumya (tildrakizumab): Phase 4 readout est. (NCT05390515)
DESCRIPTION:Ilumya (tildrakizumab)\, phase 4\, Psoriasis.\nStudy: Psoriatic
  Immune Response to Tildrakizumab\nEstimated primary completion: 1 Septemb
 er 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/tildrakizuma
 b#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05
 390515
URL:https://assetmemo.bio/drug/tildrakizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04991116-99@assetmemo.bio
DTSTAMP:20261121T004944Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Ilumya (tildrakizumab): Phase 3 readout est. (NCT04991116)
DESCRIPTION:Ilumya (tildrakizumab)\, phase 3\, Psoriatic Arthritis.\nStudy:
  Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients 
 With Psoriatic Arthritis\nEstimated primary completion: December 2028. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/tildrakizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT04991116
URL:https://assetmemo.bio/drug/tildrakizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
